The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: A randomised, double-blind, placebo-controlled study

British Journal of Nutrition

Volumn 114, Issue 5, 2015, Pages 796-803

  Faghihzadeh, Forouzan ^a   Adibi, Payman ^b   Hekmatdoost, Azita ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clinical trials; Fatty liver; Inflammation; Non alcoholic fatty liver disease; Resveratrol

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RESVERATROL; TRIACYLGLYCEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; PLANT EXTRACT; STILBENE DERIVATIVE;

ADULT; ANTHROPOMETRY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; ENERGY BALANCE; FEMALE; FOLLOW UP; HUMAN; INSULIN RESISTANCE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; WAIST CIRCUMFERENCE; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DIET SUPPLEMENTATION; DRUG EFFECTS; FATTY LIVER; LIPID METABOLISM; LIVER; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYTOTHERAPY; RISK FACTOR;

ADULT; ALANINE TRANSAMINASE; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BIOMARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYTOTHERAPY; PLANT EXTRACTS; RISK FACTORS; STILBENES; TRIGLYCERIDES;

EID: 84940609721     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114515002433     Document Type: Article

References (35)

1. Angulo P (2007) GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 25, 883-889.
2. Law K & Brunt EM (2010) Nonalcoholic fatty liver disease. Clin Liver Dis 14, 591-604.
3. Yilmaz Y (2012) Review article: is non-alcoholic fatty liver disease a spectrum: or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 36, 815-823.
4. Ghaemi A, Taleban FA, Hekmatdoost A, et al. (2013) How much weight loss is effective on nonalcoholic fatty liver disease? Hepat Mon 13, e15227.
5. Elias MC, Parise ER, L de Carvalho, et al. (2010) Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease. Nutrition 26, 1094-1099.
6. Faghihzadeh F, Adibi P, Rafiei R, et al. (2014) Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res 34, 837-843.
7. Eslamparast T, Zamani F, Hekmatdoost A, et al. (2014) Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome: a randomised, double-blind, placebo-controlled pilot study. Br J Nutr 112, 438-445.
8. Eslamparast T, Poustchi H, Zamani F, et al. (2014) Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr 99, 535-542.
9. Askari F, Rashidkhani B & Hekmatdoost A (2014) Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients. Nutr Res 34, 143-148.
10. Furimsky AM, Green CE, Hunt Sharp LE, et al. (2008) Effect of resveratrol on 17β-estradiol sulfation by human hepatic and jejunal S9 and recombinant sulfotransferase 1E1. Drug Metab Dispos 36, 129-136.
11. Timmers S, Konings E, Bilet L, et al. (2011) Calorie restrictionlike effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 14, 612-622.
12. Bhatt JK, Thomas S & Nanjan MJ (2012) Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 32, 537-541.
13. Brasnyó P, Molnár GA, Mohás M, et al. (2011) Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 106, 383-389.
14. Petta S, Muratore C & Craxi A (2009) Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 41, 615-625.
15. National Institutes of Health, National Heart, Lung, and Blood Institute and North American Association for the Study of Obesity (2000) Initiative NOE, The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute and North American Association for the Study of Obesity.
16. Ainsworth BE, Haskell WL, Whitt MC, et al. (2000) Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 32, Suppl. 1, S498-S504.
17. Yang SJ & Lim Y (2014) Resveratrol ameliorates hepatic metainflammation and inhibits NLRP3 inflammasome activation. Metabolism 63, 693-701.
18. Li L, Hai J, Li Z, et al. (2014) Resveratrol modulates autophagy and NF-kappa B activity in a murine model for treating nonalcoholic fatty liver disease. Food Chem Toxicol 63, 166-173.
19. Labbé A, Garand C, Cogger VC, et al. (2011) Resveratrol improves insulin resistance hyperglycemia and hepatosteatosis but not hypertriglyceridemia, inflammation, and life span in a mouse model for Werner syndrome. J Gerontol A Biol Sci Med Sci 66A, 264-278.
20. Burgess TA, Robich MP, Chu LM, et al. (2011) Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle. Arch Surg 146, 556-564.
21. Shang J, Chen LL & Xiao FX (2008) Resveratrol improves nonalcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 29, 698-706.
22. Bujanda L, Hijona E, Larzabal M, et al. (2008) Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol 8, 40.
23. Qiao Y, Sun J, Xia S, et al. (2014) Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fatinduced obesity. Food Funct 5, 1241.
24. Choi YJ, Suh HR, Yoon Y, et al. (2014) Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase. Arch Pharm Res 37, 1169-1176.
25. Xin P, Han H, Gao D, et al. (2013) Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats. Food Chem Toxicol 52, 12-18.
26. Gómez-Zorita S, Fernández-Quintela A, MacArulla MT, et al. (2012) Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr 107, 202-210.
27. Chachay VS, Macdonald GA, Martin JH, et al. (2014) Resveratrol does not benefit patients with non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol 12, 2092-2103.
28. Bo S, Ciccone G, Castiglione A, et al. (2013) Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, crossover trial. Curr Med Chem 20, 1323-1331.
29. Cho S-J, Jung UJ & Choi M-S (2012) Differential effects of lowdose resveratrol on adiposity and hepatic steatosis in dietinduced obese mice. Br J Nutr 108, 2166-2175.
30. Poulsen MM, Vestergaard PF, Clasen BF, et al. (2013) Highdose resveratrol supplementation in obese men an investigator- initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 62, 1186-1195.
31. Yoshino J, Conte C, Fontana L, et al. (2012) Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab 16, 658-664.
32. Crandall JP, Oram V, Trandafirescu G, et al. (2012) Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci 67, 1307-1312.
33. Rivera L, Morón R, Zarzuelo A, et al. (2009) Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 77, 1053-1063.
34. Thirunavukkarasu M, Penumathsa SV, Koneru S, et al. (2007) Resveratrol alleviates cardiac dysfunction in streptozotocininduced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 43, 920-929.
35. Malekzadeh R & Poustchi H (2011) Fibroscan for assessing liver fibrosis: an acceptable alternative for liver biopsy: fibroscan: an acceptable alternative for liver biopsy. Hepat Mon 11, 157-158.